Cargando…

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial

A novel cancer vaccine consisting of 20 mixed peptides (KRM-20) was designed to induce cytotoxic T lymphocytes (CTL) against twelve different tumor-associated antigens. The aim of this phase II trial was to examine whether KRM-20 in combination with docetaxel and dexamethasone enhances the antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi, Masanori, Arai, Gaku, Egawa, Shin, Ohyama, Chikara, Naito, Seiji, Matsumoto, Kazumasa, Uemura, Hirotsugu, Nakagawa, Masayuki, Nasu, Yasutomo, Eto, Masatoshi, Suekane, Shigetaka, Sasada, Tetsuro, Shichijo, Shigeki, Yamada, Akira, Kakuma, Tatsuyuki, Itoh, Kyogo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183507/ https://www.ncbi.nlm.nih.gov/pubmed/32025848 http://dx.doi.org/10.1007/s00262-020-02498-8

Ejemplares similares

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes from Tumor‐infiltrating Lymphocytes of a Patient with Testicular Embryonal Cancer
por: Suekane, Shigetaka, et al.
Publicado: (1997)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

Expression of the SART‐1 Antigens in Uterine Cancers
por: Matsumoto, Hajime, et al.
Publicado: (1998)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
por: Muroya, Daisuke, et al.
Publicado: (2016)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Detection of MAGE‐4 Protein in the Sera of Patients with Hepatitis‐C Virus‐associated Hepatocellular Carcinoma and Liver Cirrhosis
por: Tsuzurahara, Shin‐ichi, et al.
Publicado: (1997)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Identification of Cyclophilin B‐derived Peptides Capable of Inducing Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes
por: Tamura, Mayumi, et al.
Publicado: (2001)

Elevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis
por: Yutani, Shigeru, et al.
Publicado: (2002)

Expression of MAGE‐1 Gene by Esophageal Carcinomas
por: Toh, Yuji, et al.
Publicado: (1995)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Expression of Tumor‐rejection Antigens in Gynecologic Cancers
por: Tanaka, Shoko, et al.
Publicado: (2000)

Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor‐rejection Antigen SART‐1
por: Gotoh, Masashi, et al.
Publicado: (1998)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
por: Shichijo, Shigeki, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_2bnd0th1jpp6vqegtmb1oidh5a